Completion of Recruitment in PANCOSIL Study

News

Completion of Recruitment in PANCOSIL Study

Sydney, Australia – 4 July 2025: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce the successful completion of patient recruitment for the PANCOSIL Investigator Initiated Study. Achieving this milestone is yet another important step in the Company’s well-articulated clinical development strategy.

OncoSil™ device’s clinical development accelerated by PANCOSIL study

The PANCOSIL study is an open-label, single-arm Phase 1–2 feasibility trial initiated by Amsterdam University Medical Center (Amsterdam UMC) in the Netherlands. The study is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer (LAPC). OncoSil Medical announced ethics committee approval for the PANCOSIL study on 5 June 2023 and first patient treatment on 29 November 2023.

A total of 20 patients have now been enrolled in the study. Its primary objective is to assess a novel delivery method for the OncoSil™ device via a CT-guided percutaneous approach. This approach has the potential to simplify administration and lower barriers to adoption, supporting wider market penetration and real-world clinical use.

This innovative method represents a potentially transformative step in how OncoSil™ therapy can be delivered—providing a less invasive and more accessible option for treatment centres worldwide.

OncoSil Medical anticipates preliminary data from the PANCOSIL study to be available in late calendar 2025.

Professor Marc Besselink, Lead Investigator at Amsterdam UMC, said:

“By achieving full recruitment, the PANCOSIL study opens a new chapter in the evolution of localised treatment of pancreatic cancer. By developing CT-guided percutaneous administration under local anaesthesia, we will make OncoSil therapy more broadly applicable. The study has the potential to redefine the delivery model and bring meaningful benefits to both clinicians and patients.”

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“The completion of recruitment in the PANCOSIL study represents a critical milestone in the clinical development of the OncoSil™ device. On behalf of OncoSil Medical, I want to thank Professor Besselink and the entire Amsterdam UMC team for their leadership and vision over the design and implementation stages of the PANCOSIL study. The study’s importance to our device’s development process cannot be overestimated, with it representing a major opportunity to unlock new pathways for delivering our therapy and accelerating its adoption in clinical practice. We now look forward to the results from the PANCOSIL study and expect that they will make an invaluable contribution to our efforts to make the OncoSil™ device a go-to treatment for patients with unresectable locally advanced pancreatic cancer – one that has acknowledged flexibility and is widely accessible.”